BioVaxys and SpayVac Enhance Capacity for Wildlife Vaccines
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) has teamed up with SpayVac for Wildlife, Inc., announcing significant advancements in their vaccine production capabilities. Their recent collaboration has led to SpayVac's facility reaching full operational status, enabling it to meet the growing demand for its innovative contraceptive vaccines.
Advancements in Vaccine Production
The efficiency of the newly operational laboratory and production facility means SpayVac can now distribute its renowned pZP vaccine and the latest GnRH vaccine for a variety of species, marking a critical moment in wildlife contraception management.
Broadening Availability
This enhancement is not just a technical accomplishment; it opens doors for broader field trials and market assessments, signaling an upcoming launch of SpayVac products. SpayVac's CEO, Tom D'Orazio, expressed excitement about utilizing funds from ongoing fundraising to produce tens of thousands of vaccines, aiming to cater to diverse animal contraception needs.
Global Impact on Animal Population Control
The expanded production has already proven beneficial, with substantial shipments sent to support a major feral horse population management project in Europe. This initiative illustrates SpayVac's commitment to enhancing global efforts in animal population control.
Research Collaborations
Veterinary expert and SpayVac VP of Research and Development, Ursula Bechert, DVM, PhD, noted ongoing collaborations with various stakeholders, including government sectors and aquaculture genetics companies. These relationships aim to explore alternatives to traditional fertility regulation methods, enhancing sustainability in wildlife management.
Innovative Technology at Work
SpayVac employs a patented liposome-based antigen delivery platform, licensed from BioVaxys, which has shown efficiency in eliciting robust immune responses. This technology promises to deliver single-dose vaccines that remain effective for years, catering to both wildlife and agricultural animals.
BioVaxys' Broader Vision
BioVaxys is also making strides in creating its own vaccines utilizing the advantageous liposome technology for human health issues, including cancers and infectious diseases. The company is advancing several clinical programs focusing on patient care through innovative treatments.
Strategic Leadership and Future Goals
Kenneth Kovan, BioVaxys' President & Chief Operating Officer, shared insights on how SpayVac's enhanced capabilities will fast-track product development. This leap forward will empower SpayVac to expand its portfolio efficiently, utilizing BioVaxys' robust technological platforms.
About SpayVac for Wildlife, Inc.
SpayVac for Wildlife, Inc. designs humane fertility-control vaccines that demonstrate effectiveness across numerous species with minimal environmental impact. Their innovative approach leverages proprietary technology to create multi-year effectiveness from a single injection.
About BioVaxys Technology Corp.
BioVaxys Technology Corp., a clinical-stage biopharmaceutical firm, aims to revolutionize patient care through novel immunotherapies leveraging its unique DPX™ immune-educating and HapTenix© platforms, targeting various conditions including cancers and allergies.
Contact Information
For inquiries about SpayVac or BioVaxys Technology Corp., please feel free to reach out to their respective teams, ensuring swift communication regarding research developments and corporate initiatives.
Frequently Asked Questions
What is the partnership between BioVaxys and SpayVac?
This partnership focuses on enhancing vaccine production for wildlife, particularly in contraceptive solutions.
What vaccines are being produced?
They are producing pZP and GnRH vaccines, targeting various wildlife species for fertility control.
Where is the production facility located?
The production facility is based in Madison, where it has begun scaling operations to meet demand.
What is the significance of the increased production?
The increased production capacity allows for broader market testing and prepares for future launches of ??ayVac products.
How does SpayVac's technology work?
SpayVac uses a liposome-based antigen delivery system, enabling effective vaccines with a long lifespan from a single dose.
